HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer
ConditionLiver Cancer
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorShanghai Zhongshan Hospital
About this trial
To provide evidence-based medical evidence for the optimized combination strategy of local and systemic therapies.
Eligibility criteria
Qualifiers
Age 18-80 years.
Diagnosed with hepatocellular carcinoma (HCC) in accordance with the Standardization for Diagnosis and Treatment of Primary Hepatic Carcinoma (2024 Edition) issued by the National Health Commission of the People's Republic of China.
BCLC stage B or C, with no indication or refusal of surgical treatment, and measurable lesions meeting the mRECIST (Modified Response Evaluation Criteria in Solid Tumors) criteria on baseline imaging.
Child-Pugh liver function grade A or well-compensated grade B (score ≤7).
Disqualifiers
Prior transarterial chemoembolization (TACE) or other local therapies for HCC (except bridging liver transplantation).
Active viral hepatitis (hepatitis B or C) with pre-treatment viral load >100 IU/mL (positive for HCV RNA or HBV DNA) or without consistent antiviral therapy.
Alcohol abuse or pregnancy.
Concurrent other malignancies or history of other malignancies within the past 3 years.
Trial design
Treatments tested in this trial
- HTAC
- HAC
- TAC
Treatment groups
315 Participants
are divided into 3 treatment groupsLocations
Sponsors and collaborators
Shanghai Zhongshan Hospital
Lead sponsor
Affiliated Hospital of Nantong University
Collaborator
Nantong First People's Hospital
Collaborator
The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China
Collaborator
Shandong Public Health Clinical Center
Collaborator
Shanghai Xuhui Hospital
Collaborator
The fifth Hospital Affiliated To WZMU
Collaborator
Source ClinicalTrials.gov